![tirzepatide lawsuit 2025 Zepbound [2026 Update] March 10, 2025: Patients transitioning](https://www.robertkinglawfirm.com/wp-content/uploads/2024/11/zepbound-lawsuit-timeline.webp)
tirzepatide lawsuit 2025 Zepbound [2026 Update] March 10, 2025: Patients transitioning
Description
Clinicallyrelevant weight loss is achieved independently of early weight loss response to onceweekly subcutaneous semaglutide 2.4 MG (STEP 4)
![tirzepatide lawsuit 2025 Zepbound [2026 Update] March 10, 2025: Patients transitioning](https://www.safemedicines.org/wp-content/uploads/2024/12/470202312_600416762546172_8892501713677863747_n.jpg)
Weight loss: 3 to 8% of body weight over 3 to 6 months for users who respond
![tirzepatide lawsuit 2025 Zepbound [2026 Update] March 10, 2025: Patients transitioning](https://thehill.com/wp-content/uploads/sites/2/2023/11/654bf4321d7969.11613537-e1705002282406.jpeg?strip=1)
Firm or thickened skin: Sometimes a hard lump or thicker area of skin (induration) may appear
![tirzepatide lawsuit 2025 Zepbound [2026 Update] March 10, 2025: Patients transitioning](https://www.robertkinglawfirm.com/wp-content/uploads/2026/04/wegovy-lawsuit-timeline-670x1024.webp)
Some people respond better to one than the other
